AKT in cancer: new molecular insights and advances in drug development

由 Mundi, Prabhjot S., Sachdev, Jasgit, McCourt, Carolyn, Kalinsky, Kevin
發表在 Br J Clin Pharmacol (2016)

Does Race Affect Outcomes in Triple Negative Breast Cancer?

由 Sachdev, Jasgit C., Ahmed, Saira, Mirza, Muhammad M., Farooq, Aamer, Kronish, Lori, Jahanzeb, Mohammad
出版 2010

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

由 Beg, Muhammad S., Brenner, Andrew J., Sachdev, Jasgit, Borad, Mitesh, Kang, Yoon-Koo, Stoudemire, Jay, Smith, Susan, Bader, Andreas G., Kim, Sinil, Hong, David S.
發表在 Invest New Drugs (2016)

TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (...

由 Anders, Carey, Munster, Pamela, Northfelt, Donald, Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Sachdev, Jasgit C
發表在 Neurooncol Adv (2019)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

由 Sachdev, Jasgit C., Munster, Pamela, Northfelt, Donald W., Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Thiagalingam, Arunthathi, Anders, Carey
發表在 Breast Cancer Res Treat (2020)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

由 Werner, Theresa L., Sachdev, Jasgit, Swisher, Elizabeth M., Gutierrez, Martin, Kittaneh, Muaiad, Stein, Mark N., Xiong, Hao, Dunbar, Martin, Sullivan, Danielle, Komarnitsky, Philip, McKee, Mark, Tan, Antoinette R.
發表在 Cancer Med (2018)

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

由 Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Niels, Ramanathan, Ramesh K., Sarantopoulos, John, Völkel, Dirk, Youssef, Ashraf, de Jong, Floris A., Tsimberidou, Apostolia Maria
發表在 Br J Clin Pharmacol (2020)

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

由 Lin, Chia-Chi, Arkenau, Hendrik-Tobias, Lu, Sharon, Sachdev, Jasgit, de Castro Carpeño, Javier, Mita, Monica, Dziadziuszko, Rafal, Su, Wu-Chou, Bobilev, Dmitri, Hughes, Lorraine, Chan, Jian, Zhang, Zhi-Yi, Weiss, Glen J.
發表在 Br J Cancer (2019)

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

由 de Bono, Johann, Ramanathan, Ramesh K., Mina, Lida, Chugh, Rashmi, Glaspy, John, Rafii, Saeed, Kaye, Stan, Sachdev, Jasgit, Heymach, John, Smith, David C., Henshaw, Joshua W., Herriott, Ashleigh, Patterson, Miranda, Curtin, Nicola J., Byers, Lauren Averett, Wainberg, Zev A.
發表在 Cancer Discov (2017)

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

由 Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.
發表在 Br J Cancer (2020)

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

由 Kalinsky, Kevin, Hong, Fangxin, McCourt, Carolyn K., Sachdev, Jasgit C., Mitchell, Edith P., Zwiebel, James A., Doyle, L. Austin, McShane, Lisa M., Li, Shuli, Gray, Robert J., Rubinstein, Larry V., Patton, David, Williams, Paul M., Hamilton, Stanley R., Conley, Barbara A., O’Dwyer, Peter J., Harris, Lyndsay N., Arteaga, Carlos L., Chen, Alice P., Flaherty, Keith T.
發表在 JAMA Oncol (2020)

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

由 Konstantinopoulos, Panagiotis A., Waggoner, Steven, Vidal, Gregory A., Mita, Monica, Moroney, John W., Holloway, Robert, Van Le, Linda, Sachdev, Jasgit C., Chapman-Davis, Eloise, Colon-Otero, Gerardo, Penson, Richard T., Matulonis, Ursula A., Kim, Young Bae, Moore, Kathleen N., Swisher, Elizabeth M., Färkkilä, Anniina, D’Andrea, Alan, Stringer-Reasor, Erica, Wang, Jing, Buerstatte, Nathan, Arora, Sujata, Graham, Julie R., Bobilev, Dmitri, Dezube, Bruce J., Munster, Pamela
發表在 JAMA Oncol (2019)

Hepatobiliary Cancers: Clinical Practice Guidelines in Oncology™

由 Benson, Al B., Abrams, Thomas A., Ben-Josef, Edgar, Bloomston, P. Mark, Botha, Jean F., Clary, Bryan M., Covey, Anne, Curley, Steven A., D'Angelica, Michael I., Davila, Rene, Ensminger, William D., Gibbs, John F., Laheru, Daniel, Malafa, Mokenge P., Marrero, Jorge, Meranze, Steven G., Mulvihill, Sean J., Park, James O., Posey, James A., Sachdev, Jasgit, Salem, Riad, Sigurdson, Elin R., Sofocleous, Constantinos, Vauthey, Jean-Nicolas, Venook, Alan P., Goff, Laura Williams, Yen, Yun, Zhu, Andrew X.
發表在 J Natl Compr Canc Netw (2009)